Reuters logo
3 months ago
BRIEF-Selexis and Ose Immunotherapeutics sign commercial license agreement to further advance development of Ose's interleukin receptor 7 antagonist
May 23, 2017 / 3:51 PM / 3 months ago

BRIEF-Selexis and Ose Immunotherapeutics sign commercial license agreement to further advance development of Ose's interleukin receptor 7 antagonist

May 23 (Reuters) - Ose Immunotherapeutics SA:

* SELEXIS AND OSE IMMUNOTHERAPEUTICS SIGN COMMERCIAL LICENSE AGREEMENT TO FURTHER ADVANCE DEVELOPMENT OF OSE'S INTERLEUKIN RECEPTOR 7 ANTAGONIST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below